# Gene Therapy Clinical Trial for the Treatment of Leber's Hereditary Optic Neuropathy Associated With ND1 Mutations

> **NCT05820152** · PHASE1,PHASE2 · TERMINATED · sponsor: **Neurophth Therapeutics Inc** · enrollment: 11 (actual)

## Conditions studied

- Leber Hereditary Optic Neuropathy (LHON)

## Interventions

- **DRUG:** NFS-02 Injection

## Key facts

- **NCT ID:** NCT05820152
- **Lead sponsor:** Neurophth Therapeutics Inc
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2023-08-15
- **Primary completion:** 2024-06-24
- **Final completion:** 2024-06-24
- **Target enrollment:** 11 (ACTUAL)
- **Why stopped:** Due to the sponsor circumstances and external reasons
- **Last updated:** 2024-09-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05820152

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05820152, "Gene Therapy Clinical Trial for the Treatment of Leber's Hereditary Optic Neuropathy Associated With ND1 Mutations". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05820152. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*